Objective: To test the hypothesis that sublingual captopril produces a
more rapid improvement of acute pulmonary edema (APE) than does place
bo, when added to a standard regimen of O-2, nitrates, morphine, and f
urosemide. Methods: Prospective, randomized, double-blind, placebo-con
trolled clinical trial in an urban teaching hospital ED. Adults brough
t to the ED with APE were given captopril or placebo sublingually. Eve
ry 5 minutes a clinical APE distress score (APEX) was obtained. Result
s: Over the first 40 minutes of treatment, the mean APEXs were signifi
cantly better for the patients given captopril [p < 0.001, F = 14.5, o
ne-way (repeated-measures) analysis of variance (ANOVA)]. At 30 minute
s, the patients given captopril had a mean APEX improvement of 43% (i.
e., to 57% of initial distress); the group given the current standard
regimen plus placebo improved only 25% (i.e., to 75% of initial distre
ss; p = 0.03, multiway ANOVA), In addition, there was less respiratory
failure necessitating mechanical ventilation in the captopril patient
s (9%) vs the placebo patients (20%), which did not achieve significan
ce (p = 0.10, Fisher's exact test). Conclusion: In APE, the addition o
f sublingual captopril to the standard regimen of O-2, nitrates, morph
ine, and furosemide produces more rapid clinical improvement than does
the standard regimen alone.